|Part I. Considerations for Treating Patients on Bisphosphonate Therapy
Bisphosphonates, as well as some new "antiresorptive" drugs, are known to cause exposed necrotic bone in the jaws. Their common mechanism of action is impairment or death of osteoclasts that remodel and renew bone. This session will distinguish between all of the current drugs in the market and their delivery (intravenous, subcutaneous, or oral) related to severity, prevention protocols, treatment protocols, and how they may impact dental treatment including dental implants, occlusal loading, and periodontal and oral surgical procedure.
Part II. Bone Grafting for Ridge Augmentation and Jaw Defects: Using BMP in Today's Dental Practice
Today, dental practitioners have many bone-grafting materials available to them, including cell products, recombinant proteins, allogeneic bone, xenogeneic bone, and synthetics, among others. Each may be useful in limited circumstances or in select indications, and each regnerates bone at different rates and to different degrees. It is prudent for the clinician to understand the contribution of each of the commonly used graft materials. This session will focus on tissue-engineering principles specific to the use of rhBMP to replace autogenous bone grafting.
CE Credits: 5 hours
ABOUT THE SPEAKER
Robert E. Marx, DDS, is chief of the Division of Oral and Maxillofacial Surgery at the University of Miami Miller School of Medicine. A well-known educator, researcher, and innovative surgeon, he has developed new concepts and treatments for pathologies of the oral and maxillofacial area as well as new techniques in reconstructive surgery. Among other accomplishments, he pioneered the clinical applications of rhBMP and stem cell use and was the first to identify what is now known worldwide as bisphosphonate-induced osteonecrosis of the jaws.
9:00 AM 10:30 AM
10:30 AM 10:45 AM
10:45 AM 12:30 PM
12:30 PM 1:15 PM
1:15 PM 3:00 PM